# Clinical trials recruiting in Utah: 1,312 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,312 trials recruiting or not yet recruiting with a site in Utah, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Utah: 1,312 rows for $65.60, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 27 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/utah

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,312
- Recruiting or not yet: 1,312
- Read on: November 19, 2026

## Trials

The 25 newest of 1,312, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945431 | A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction | South Rampart Pharma, Inc. | Phase 2 | Not yet recruiting | Acute Pain, Postoperative Pain, Pain, Dental Pain | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945431) |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 16, 2026 | NCT07939815 | A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Bristol-Myers Squibb | Phase 1/2 | Not yet recruiting | Advanced Solid Malignancies | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939815) |
| November 16, 2026 | NCT07937657 | A Study to Evaluate the Safety and Pain Relief of MAX-001 After Surgical Removal of Wisdom Teeth | Maxona Pharmaceuticals, Inc. | Phase 2 | Not yet recruiting | Impacted Third Molar Tooth, Tooth Extraction Status Nos | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937657) |
| November 13, 2026 | NCT07935304 | A Study Assessing Eloralintide (LY3841136) in Healthy Participants | Eli Lilly and Company | Phase 1 | Not yet recruiting | Healthy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935304) |
| November 12, 2026 | NCT07932301 | Pre-Transplant Nutrition Counseling in Patients With Multiple Myeloma | University of Utah | Not applicable | Not yet recruiting | Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932301) |
| November 12, 2026 | NCT07931599 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931599) |
| November 12, 2026 | NCT07931573 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931573) |
| November 10, 2026 | NCT07928258 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors | Eli Lilly and Company | Phase 1 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung, Stomach... | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928258) |
| November 9, 2026 | NCT07926321 | A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment | Boehringer Ingelheim | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926321) |
| November 5, 2026 | NCT07918859 | A Study of Imlunestrant (LY3484356) in Healthy Female Participants | Eli Lilly and Company | Phase 1 | Not yet recruiting | Healthy | 343 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918859) |
| November 4, 2026 | NCT07915882 | Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions | Sponsor not shown (see the record) | Not applicable | Recruiting | Methamphetamine-Associated Heart Failure, Methamphetamine-Associated Pulmonary Arterial Hypertension | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915882) |
| November 4, 2026 | NCT07915245 | A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915245) |
| November 4, 2026 | NCT07915219 | A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Bronchiectasis | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915219) |
| October 30, 2026 | NCT07906717 | A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 3 | Recruiting | Prostatic Neoplasms | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906717) |
| October 29, 2026 | NCT07905183 | A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs | Enliven Therapeutics | Phase 3 | Recruiting | Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic... | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905183) |
| October 29, 2026 | NCT07905105 | A Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction | Cytogel Pharma, LLC | Phase 1/2 | Recruiting | Acute Postoperative Pain, Dental Pain | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905105) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 27, 2026 | NCT07897656 | Monitored Anesthesia Care and Soft Tissue Infiltration With Local Anesthesia Feasibility Trial | NYU Langone Health | Not applicable | Recruiting | Hip Fracture Surgeries, Intertrochanteric Fracture, Femoral Hip Fracture | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897656) |
| October 26, 2026 | NCT07895966 | Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis | University of Utah | Phase 2 | Not yet recruiting | Erythrocytosis, Pulmonary Hypertension, Thrombosis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895966) |
| October 26, 2026 | NCT07895134 | Psilocybin for Depression in Veterans | VA Office of Research and Development | Phase 2 | Not yet recruiting | Major Depression | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895134) |
| October 23, 2026 | NCT07893093 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants... | Ascletis Pharma (China) Co., Limited | Phase 1 | Recruiting | Chronic Weight Management | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893093) |
| October 23, 2026 | NCT07891780 | Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients | Hikma Pharmaceuticals USA Inc. | Phase 2 | Not yet recruiting | Epinephrine, Hypersensitivity, Immediate, Anaphylaxis | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891780) |
| October 22, 2026 | NCT07887880 | A Novel Multimodal Approach to Promote Motor Recovery and Plasticity After Stroke | University of Utah | Not applicable | Recruiting | Stroke | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887880) |
| October 21, 2026 | NCT07887763 | A Phase 1 Study to Evaluate Safety, Tolerability, and Drug Levels of BMS-986485 in Healthy Adult Participants | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Healthy Volunteers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887763) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| University of Utah | Salt Lake City | 214 |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | 84 |
| Huntsman Cancer Institute | Salt Lake City | 66 |
| Primary Children's Hospital | Salt Lake City | 61 |
| Intermountain Medical Center | Murray | 56 |
| START Mountain Region | West Valley City | 38 |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | 35 |
| Intermountain Health | Murray | 27 |
| University of Utah Health | Salt Lake City | 26 |
| VA Salt Lake City Health Care System, Salt Lake City, UT | Salt Lake City | 22 |
| University of Utah Hospital | Salt Lake City | 22 |
| Huntsman Cancer Institute at University of Utah | Salt Lake City | 21 |
| University of Utah Sugarhouse Health Center | Salt Lake City | 16 |
| Intermountain Healthcare | Salt Lake City | 15 |
| Utah Cancer Specialists | Salt Lake City | 14 |
| Farmington Health Center | Farmington | 13 |
| Huntsman Cancer Institute at the University of Utah | Salt Lake City | 12 |
| LDS Hospital | Salt Lake City | 12 |
| University of Utah Huntsman Cancer Institute | Salt Lake City | 12 |
| The University of Utah | Salt Lake City | 10 |
| University of Utah - Huntsman Cancer Institute | Salt Lake City | 9 |
| Alpine Research Organization | Layton | 9 |
| Saint George Regional Medical Center | St. George | 9 |
| University of Utah Healthcare | Salt Lake City | 9 |
| South Jordan Health Center | South Jordan | 9 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 8 |
| Phase 1 | 135 |
| Phase 1/2 | 107 |
| Phase 2 | 225 |
| Phase 2/3 | 39 |
| Phase 3 | 381 |
| Phase 4 | 29 |
| Not applicable | 222 |
| Observational | 166 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 63 |
| Neoplasms | 46 |
| Breast Neoplasms | 43 |
| Colorectal Neoplasms | 37 |
| Obesity | 35 |
| Neoplasm Metastasis | 29 |
| Ovarian Neoplasms | 29 |
| Prostatic Neoplasms | 28 |
| Endometrial Neoplasms | 28 |
| Multiple Myeloma | 27 |
| Heart Failure | 26 |
| Pancreatic Neoplasms | 25 |
| Lung Neoplasms | 25 |
| Diabetes Mellitus, Type 2 | 24 |
| Cardiovascular Diseases | 24 |
| Melanoma | 24 |
| Triple Negative Breast Neoplasms | 22 |
| Squamous Cell Carcinoma of Head and Neck | 22 |
| Recurrence | 21 |
| Overweight | 21 |
| Stroke | 18 |
| Leukemia, Myeloid, Acute | 18 |
| Depressive Disorder, Major | 17 |
| Lymphoma, Large B-Cell, Diffuse | 16 |
| Lymphoma | 16 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Utah | 136 |
| National Cancer Institute (NCI) | 43 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 39 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 29 |
| VA Office of Research and Development | 22 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 21 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 19 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 19 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 19 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 18 |
| Children's Oncology Group | 18 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 16 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 14 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 14 |
| SWOG Cancer Research Network | 13 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 12 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 12 |
| Alliance for Clinical Trials in Oncology | 11 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 10 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 10 |
| NRG Oncology | 9 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 9 |
| Duke University | 8 |
| Intermountain Health Care, Inc. | 8 |
| University of Pennsylvania | 7 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Utah

- [Commercial printers in Utah, United States](https://specstream.ai/data/businesses/commercial-printers/utah-united-states)
- [Home automation companies in Utah, United States](https://specstream.ai/data/businesses/home-automation-companies/utah-united-states)
- [Orthodontics practices in Utah, United States](https://specstream.ai/data/businesses/orthodontics-practices/utah-united-states)
- [Thai restaurants in Utah, United States](https://specstream.ai/data/businesses/thai-restaurants/utah-united-states)
- [Cabinet makers in Utah, United States](https://specstream.ai/data/businesses/cabinet-makers/utah-united-states)
- [Fire protection companies in Utah, United States](https://specstream.ai/data/businesses/fire-protection-companies/utah-united-states)
